microRNA‑605 promotes cell proliferation, migration and invasion in non‑small cell lung cancer by directly targeting LATS2 Retraction in /10.3892/etm.2022.11415

Ye,Ying; Zhuang,Juhua; Wang,Guoyu; He,Saifei; Ni,Jing; Xia,Wei; Wang,Jiening

doi:10.3892/etm.2017.4538

microRNA‑605 promotes cell proliferation, migration and invasion in non‑small cell lung cancer by directly targeting LATS2

Retraction in: /10.3892/etm.2022.11415

Authors:
- Ying Ye
- Juhua Zhuang
- Guoyu Wang
- Saifei He
- Jing Ni
- Wei Xia
- Jiening Wang
View Affiliations

Affiliations: Department of Nuclear Medicine, The Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China
Published online on: June 1, 2017 https://doi.org/10.3892/etm.2017.4538
Pages: 867-873

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common cause of cancer‑ associated mortality for men and women worldwide. An increasing number of studies have reported that the abnormal expression of microRNAs contributes to the pathogenesis of the majority of human cancer types, including non‑small cell lung cancer (NSCLC). The present study aimed to measure microRNA‑650 (miR‑650) expression in NSCLC and evaluate its function in NSCLC cells. Reverse transcription‑quantitative polymerase chain reaction was used to determine miR‑650 expression in NSCLC tissue samples and cell lines. Assays for cell proliferation, migration and invasion were performed to investigate the roles of miR‑650 on NSCLC progression. Furthermore, the mechanisms underlying the effects of miR‑650 on NSCLC cell growth and metastasis were determined. In the current study, miR‑650 was demonstrated to be highly expressed in NSCLC tissue samples and cell lines. Inhibition of expression of miR‑650 suppressed NSCLC cell proliferation, migration and invasion in vitro. Additionally, large tumor suppressor kinase 2 (LATS2) was identified as a direct target gene of miR‑650 in NSCLC. LATS2 was revealed to be significantly downregulated in NSCLC tissues and was negatively correlated with miR‑650 expression. Notably, LATS2 re‑expression decreased NSCLC cell proliferation, migration and invasion; similar to the effects induced by miR‑650 underexpression. In conclusion, the results of the current study suggest that miR‑650 may serve as an oncogene by direct targeting LATS2 in NSCLC formation and progression.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Li J, Feng Q, Wei X and Yu Y: MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1. Tumour Biol. 37:15221–15228. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ourari-Dhahri B, Ben Slima H, Ben Amar J, El Gharbi L, Ali M, Azzabi S Baccar, Aouina H and Bouacha H: Management of non small cell lung cancer. Tunis Med. 90:847–851. 2012.(In French). PubMed/NCBI
4	Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 11:645–653. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 5 Suppl 4:S389–S396. 2013.PubMed/NCBI
6	Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg DA: Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 143 Suppl 5:e314S–e340S. 2013. View Article : Google Scholar : PubMed/NCBI
7	Li C and Hong W: Research status and funding trends of lung cancer biomarkers. J Thorac Dis. 5:698–705. 2013.PubMed/NCBI
8	Kaplan JA, Liu R, Freedman JD, Padera R, Schwartz J, Colson YL and Grinstaff MW: Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. Biomaterials. 76:273–281. 2016. View Article : Google Scholar : PubMed/NCBI
9	Kanou T, Okami J, Tokunaga T, Ishida D, Kuno H and Higashiyama M: Prognostic factors in patients with postoperative brain recurrence from completely resected non-small cell lung cancer. Thorac Cancer. 6:38–42. 2015. View Article : Google Scholar : PubMed/NCBI
10	Deng XF, Jiang L, Liu QX, Zhou D, Hou B, Cui K, Min JX and Dai JG: Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: A meta-analysis. J Cardiothorac Surg. 11:282016. View Article : Google Scholar : PubMed/NCBI
11	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
12	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
13	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
14	Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and Takahashi T: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
15	Chen X, Tong ZK and Zhou JY, Yao YK, Zhang SM and Zhou JY: MicroRNA-206 inhibits the viability and migration of human lung adenocarcinoma cells partly by targeting MET. Oncol Lett. 12:1171–1177. 2016.PubMed/NCBI
16	Lin J, Xu K, Wei J, Heimberger AB, Roth JA and Ji L: MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer. J Gene Ther. 2(pii): 62016.PubMed/NCBI
17	Lin X, Yang Z, Zhang P, Liu Y and Shao G: miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2. Oncol Lett. 12:301–306. 2016.PubMed/NCBI
18	Lei T, Zhu Y, Jiang C, Wang Y, Fu J, Fan Z and Qin H: MicroRNA-320 was downregulated in non-small cell lung cancer and inhibited cell proliferation, migration and invasion by targeting fatty acid synthase. Mol Med Rep. 14:1255–1262. 2016.PubMed/NCBI
19	Mou X and Liu S: MiR-485 inhibits metastasis and EMT of lung adenocarcinoma by targeting Flot2. Biochem Biophys Res Commun. 477:521–526. 2016. View Article : Google Scholar : PubMed/NCBI
20	Visone R and Croce CM: MiRNAs and cancer. Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z and Zhang M: MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun. 395:275–280. 2010. View Article : Google Scholar : PubMed/NCBI
22	Sun B, Pu B, Chu D, Chu X, Li W and Wei D: MicroRNA-650 expression in glioma is associated with prognosis of patients. J Neurooncol. 115:375–380. 2013. View Article : Google Scholar : PubMed/NCBI
23	Mraz M, Dolezalova D, Plevova K, Kozubik K Stano, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky M, et al: MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 119:2110–2113. 2012. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Huang JY, Cui SY, Chen YT, Song HZ, Huang GC, Feng B, Sun M, De W, Wang R and Chen LB: MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One. 8:e726152013. View Article : Google Scholar : PubMed/NCBI
26	Zeng ZL, Li FJ, Gao F, Sun DS and Yao L: Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol. 107:105–110. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zuo ZH, Yu YP, Ding Y, Liu S, Martin A, Tseng G and Luo JH: Oncogenic activity of miR-650 in prostate cancer is mediated by suppression of CSR1 expression. Am J Pathol. 185:1991–1999. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wu A, Li J, Wu K, Mo Y, Luo Y, Ye H, Mai Z, Guo K, Wang Y, Li S, et al: LATS2 as a poor prognostic marker regulates non-small cell lung cancer invasion by modulating MMPs expression. Biomed Pharmacother. 82:290–297. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yao F, Liu H, Li Z, Zhong C and Fang W: Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells. Tumour Biol. 36:2049–2057. 2015. View Article : Google Scholar : PubMed/NCBI
30	Yun JH, Moon S, Lee HS, Hwang MY, Kim YJ, Yu HY, Kim Y, Han BG, Kim BJ and Kim JM: MicroRNA-650 in a copy number-variable region regulates the production of interleukin 6 in human osteosarcoma cells. Oncol Lett. 10:2603–2609. 2015.PubMed/NCBI
31	Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, Endo Y, Toji S, Tanaka H, Nishimune Y and Nojima H: Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics. 63:263–270. 2000. View Article : Google Scholar : PubMed/NCBI
32	Yang X, Yu J, Yin J, Xiang Q, Tang H and Lei X: MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Pharmazie. 67:645–651. 2012.PubMed/NCBI
33	Takahashi Y, Miyoshi Y, Morimoto K, Taguchi T, Tamaki Y and Noguchi S: Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. J Cancer Res Clin Oncol. 133:501–509. 2007. View Article : Google Scholar : PubMed/NCBI
34	Xia Y and Gao Y: MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 447:446–451. 2014. View Article : Google Scholar : PubMed/NCBI
35	Li Y, Pei J, Xia H, Ke H, Wang H and Tao W: Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene. 22:4398–4405. 2003. View Article : Google Scholar : PubMed/NCBI
36	Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T, Kelekar A and Tao W: Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res. 298:329–338. 2004. View Article : Google Scholar : PubMed/NCBI
37	Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et al: LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71:873–883. 2011. View Article : Google Scholar : PubMed/NCBI
38	Zhang K, Rodriguez-Aznar E, Yabuta N, Owen RJ, Mingot JM, Nojima H, Nieto MA and Longmore GD: Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation. EMBO J. 31:29–43. 2012. View Article : Google Scholar : PubMed/NCBI